Company: NCEL
Filing Date: 2025-06-23
Form Type: F-4/A
Source: 0001213900-25-056787
Chunk: 38

Company: NewcelX Ltd.
Filing Date: 2025-06-23
Form: F-4/A
Chunk 38
---
 including all applicable social security contributions) for the Company’s executive officers, and iv (iv) to approve the participation in the purchase of a run -offinsurance policy for the Company’s executive officers, to be effective at the time of the Merger’s completion, with coverage amounts and terms to be approved by the Board of Directors, in each case for the financial year 2025. 13.To approve the CVR Agreement on an advisory basis. 14.To approve the conversion of outstanding options and restricted stock units, or the RSUs, issued by Kadimastem into equivalent securities with identical rights in the Company at the time of the completion of the transactions contemplated by the Merger Agreement. Q.What will Kadimastem shareholders receive if the Merger is completed? As a result of the Merger, holders of Kadimastem Ordinary Shares will be entitled to receive NLS Common Shares in exchange for Kadimastem Ordinary Shares, equal to the number of Kadimastem Ordinary Shares held by each Kadimastem shareholder multiplied by the Exchange Ratio. At the effective time of the Merger, each outstanding Kadimastem Ordinary Share will be converted into the right to receive a number of NLS Common Shares equal to the Exchange Ratio, or the Merger Consideration. The Merger Agreement does not provide for an adjustment to the total number of NLS Common Shares that the holders of Kadimastem Ordinary Shares will be entitled to receive to account for changes in the market price of NLS Common Shares. Accordingly, the market value of the NLS Common Shares issued pursuant to the Merger will depend on the market value of the NLS Ordinary Shares at the time the Merger closes and could vary significantly from the market value of the NLS Common Shares on the date of this proxy statement/prospectus. No fractional NLS Common Shares will be issued in connection with the Merger. Instead, each holder of NLS Common Shares who otherwise would be entitled to receive a fractional NLS Common Share will receive such amount rounded down to the nearest whole number of NLS Common Shares. The Exchange Ratio will be determined based on a formula that is expected to result in the number of issued and outstanding Kadimastem Ordinary Shares (calculated on a fully -dilutedbasis, inclusive of Kadimastem Ordinary Shares resulting from the conversion of Kadimastem’s equity awards) being exchanged for that certain number of newly issued NLS Common Shares that will equal 85% of all issued and outstanding shares